Differentiating vasculitis from other diseases: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Eiman (talk | contribs)
nocaptcha, Administrators
3,082 edits
No edit summary
Eiman (talk | contribs)
nocaptcha, Administrators
3,082 edits
No edit summary
Line 14: Line 14:
! colspan="3" rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
! colspan="3" rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
| colspan="8" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestations'''
| colspan="8" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestations'''
! colspan="8" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Para-clinical findings
! colspan="9" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Para-clinical findings
| colspan="1" rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Gold standard'''
| colspan="1" rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Gold standard'''
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings
Line 23: Line 23:
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging
! rowspan="2" |Histopathology
|-
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" |Headache
! style="background:#4479BA; color: #FFFFFF;" align="center" |Headache
Line 46: Line 47:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
Line 59: Line 60:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Circumferential thickening of the [[arterial]] wall (Macaroni sign)
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Circumferential thickening of the [[arterial]] wall (Macaroni sign)
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[PET scan|PET-scan]], [[Cardiac]] [[CT]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[PET scan|PET-scan]], [[Cardiac]] [[CT]]
![[Granulomatous]] [[inflammation]] of [[arteries]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Arteriography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Arteriography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Coronary aneurysm]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Coronary aneurysm]]
|-
|-
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Giant cell arteritis]]
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Giant cell arteritis]]<ref name="pmid13679546">{{cite journal| author=Calvo-Romero JM| title=Giant cell arteritis. | journal=Postgrad Med J | year= 2003 | volume= 79 | issue= 935 | pages= 511-5 | pmid=13679546 | doi= | pmc=1742823 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13679546  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[ESR]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[CRP]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Stenosis]], [[Occlusion]], [[Dilatation]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Aneurysm]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mural [[inflammation]] in [[Magnetic resonance angiography|MRA]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
![[Granulomatous]] [[inflammation]] of [[arteries]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Biopsy]] 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Jaw pain]] and [[Jaw claudication|claudication]]
|-
|-
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurological disease]]
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurological disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral aneurysm]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral aneurysm]]<ref name="pmid20557771">{{cite journal| author=Stafa A, Leonardi M| title=Role of neuroradiology in evaluating cerebral aneurysms. | journal=Interv Neuroradiol | year= 2008 | volume= 14 Suppl 1 | issue=  | pages= 23-37 | pmid=20557771 | doi=10.1177/15910199080140S106 | pmc=3328052 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20557771  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Well-defined round, slightly hyperattenuating lesion
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Bulging out of the [[Lumen|main lumen]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Heterogeneous]] signal intensity in [[Magnetic resonance angiography|MRA]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!Layers of [[smooth muscle cells]], Intact [[endothelium]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Digital subtraction angiography|Digital subtraction angiography (DSA)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Nausea]], [[Vomiting]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurofibromatosis type 1]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurofibromatosis type 1]]<ref name="pmid28512424">{{cite journal| author=Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J| title=Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1. | journal=Case Rep Ophthalmol | year= 2017 | volume= 8 | issue= 1 | pages= 214-220 | pmid=28512424 | doi=10.1159/000469702 | pmc=5422752 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28512424  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[NF1|NF1 mutated gene]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Neurofibromin|Neurofibromin gene]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Bone disease|Bone abnormalities]] 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Optical coherence tomography angiography (OCTA)
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Optic nerve gliomas]] in [[MRI]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!Elongated spindle-shaped [[cells]] in [[Neurofibroma|neurofibromas]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Café au lait spot|Cafe au Lait spot]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurofibromatosis type 2]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurofibromatosis type 2]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 139: Line 145:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hearing loss]], [[Vision loss]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! rowspan="4" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
! rowspan="4" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
Line 161: Line 167:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 181: Line 188:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 201: Line 209:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 221: Line 230:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 242: Line 252:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 262: Line 273:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 282: Line 294:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 303: Line 316:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 323: Line 337:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 343: Line 358:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 363: Line 379:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 383: Line 400:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 403: Line 421:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 423: Line 442:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 443: Line 463:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 463: Line 484:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 483: Line 505:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 504: Line 527:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 524: Line 548:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 544: Line 569:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 565: Line 591:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 585: Line 612:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 607: Line 635:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 627: Line 656:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 647: Line 677:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 667: Line 698:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 688: Line 720:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 708: Line 741:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 728: Line 762:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 748: Line 783:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 768: Line 804:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 789: Line 826:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 810: Line 848:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 830: Line 869:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 851: Line 891:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 871: Line 912:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 891: Line 933:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 911: Line 954:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 931: Line 975:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 951: Line 996:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 972: Line 1,018:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 993: Line 1,040:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,013: Line 1,061:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,033: Line 1,082:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,053: Line 1,103:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,073: Line 1,124:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,093: Line 1,145:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,113: Line 1,166:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,133: Line 1,187:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,153: Line 1,208:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,174: Line 1,230:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,194: Line 1,251:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,214: Line 1,272:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,234: Line 1,293:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,254: Line 1,314:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,275: Line 1,336:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,295: Line 1,357:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,316: Line 1,379:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,336: Line 1,400:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,356: Line 1,421:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,377: Line 1,443:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,398: Line 1,465:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,418: Line 1,486:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,438: Line 1,507:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,459: Line 1,529:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,479: Line 1,550:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |

Revision as of 20:26, 22 March 2018

Vasculitis

Overview

Classification

Large-sized vessel vasculitis
Takayasu's Arteritis
Temporal Arteritis
Medium-sized vessel vasculitis
Kawasaki's Disease
Polyarteritis Nodosa
Small-sized vessel vasculitis
Churg-Strauss Syndrome
Cutaneous leukocytoclastic vasculitis
Essential cryoglobulinemic vasculitis
Henoch-Schonlein Purpura
Microscopic polyangiitis
Wegener's Granulomatosis
Variable-sized vessel vasculitis
Sjogren syndrome
Cogan syndrome
Single organ vasculitis
Primary central nervous system angiitis

Causes

Differential Diagnosis

gsEditor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Differential Diagnosis

Abbreviations: ABG= Arterial blood gas, ANP= Atrial natriuretic peptide, BNP= Brain natriuretic peptide, CBC= Complete blood count, COPD= Chronic obstructive pulmonary disease, CRP= C-reactive protein, CT= Computed tomography, CXR= Chest X-ray, DVT= Deep vein thrombosis, ESR= Erythrocyte sedimentation rate, HRCT= High Resolution CT, IgE= Immunoglobulin E, LDH= Lactate dehydrogenase, PCWP= Pulmonary capillary wedge pressure.

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other
Large-Vessel Vasculitis Takayasu arteritis[1] + +/- + - + + +/- +/- ESR Leukocytosis, Anemia ↑ CRP Aneurysmal dilatation of the aorta Blood vessel stenosis Circumferential thickening of the arterial wall (Macaroni sign) PET-scan, Cardiac CT Granulomatous inflammation of arteries Arteriography Coronary aneurysm
Giant cell arteritis[2] + - + +/- - - - +/- ESR Normal ↑ CRP Stenosis, Occlusion, Dilatation Aneurysm - Mural inflammation in MRA Granulomatous inflammation of arteries Biopsy  Jaw pain and claudication
Neurological disease Cerebral aneurysm[3] + - - - - - +/- + - Normal Normal - Well-defined round, slightly hyperattenuating lesion Bulging out of the main lumen - Heterogeneous signal intensity in MRA Layers of smooth muscle cells, Intact endothelium Digital subtraction angiography (DSA) Nausea, Vomiting
Neurofibromatosis type 1[4] +/- - +/- - - - + + NF1 mutated gene Normal Normal Neurofibromin gene Bone abnormalities  Optical coherence tomography angiography (OCTA) - Optic nerve gliomas in MRI Elongated spindle-shaped cells in neurofibromas Cafe au Lait spot
Neurofibromatosis type 2 +/- Hearing loss, Vision loss
Systemic disease Fibromuscular dysplasia
Ehlers-Danlos syndrome
Polymyalgia rheumatica (PMR)
Amyloidosis
Medium-Vessel Vasculitis Polyarteritis nodosa
Hepatitis B virus-associated polyarteritis nodosa
Kawasaki disease
Infectious disease Parvovirus B19 infection
Scarlet fever
Toxic shock syndrome
Mononucleosis
Leptospirosis
Lyme Disease
Measles
Rocky Mountain Spotted Fever
Staphylococcal Scalded Skin Syndrome
Toxic Epidermal Necrolysis
Cardiovascular disease Atrial Myxoma
Cholesterol Embolism
Segmental arterial mediolysis
Systemic disease Antiphospholipid Syndrome
Juvenile Idiopathic Arthritis
Small-Vessel Vasculitis ANCA-associated vasculitis Microscopic polyangiitis
Granulomatosis with polyangiitis (Wegener’s)
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
Hydralazine-associated ANCA-associated vasculitis
Immune complex small-vessel vasculitis Anti-glomerular basement membrane disease
Cryoglobulinemic vasculitis
Hepatitis C virus-associated cryoglobulinemic vasculitis
IgA vasculitis (Henoch-Schönlein purpura)
Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis)
Gastrointestinal disease Acute mesenteric ischemia
Cardiovascular disease Infective Endocarditis
Leukocytoclastic Vasculitis
Pulmonary disease Langerhans Cell Histiocytosis
Lung Abscess
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Asthma
Pulmonary Infarction
Renal disease Acute Poststreptococcal Glomerulonephritis
Hematologic disease Hemolytic-Uremic Syndrome
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Hypereosinophilic Syndrome
Non-Hodgkin Lymphoma
Serum Sickness
Disseminated Intravascular Coagulation
Idiopathic Thrombocytopenic Purpura
B cell lymphoproliferative disorder
Systemic disease Sarcoidosis
Legionella Infection
Systemic lupus erythematosus
Rheumatoid arthritis
Relapsing polychondritis
Variable-vessel vasculitis Behçet’s syndrome
Cogan's syndrome
Gastrointestinal disease Inflammatory Bowel Disease
Whipple's disease
Sjögren's syndrome
Single-organ vasculitis Primary central nervous system vasculitis
Infectious disease Aspergillosis
Histoplasmosis
Herpes Simplex Encephalitis
Systemic disease Eclampsia
Fibromuscular Dysplasia

References

  1. ↑ Vaideeswar P, Deshpande JR (2013). "Pathology of Takayasu arteritis: A brief review". Ann Pediatr Cardiol. 6 (1): 52–8. doi:10.4103/0974-2069.107235. PMC 3634248. PMID 23626437.
  2. ↑ Calvo-Romero JM (2003). "Giant cell arteritis". Postgrad Med J. 79 (935): 511–5. PMC 1742823. PMID 13679546.
  3. ↑ Stafa A, Leonardi M (2008). "Role of neuroradiology in evaluating cerebral aneurysms". Interv Neuroradiol. 14 Suppl 1: 23–37. doi:10.1177/15910199080140S106. PMC 3328052. PMID 20557771.
  4. ↑ Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J (2017). "Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1". Case Rep Ophthalmol. 8 (1): 214–220. doi:10.1159/000469702. PMC 5422752. PMID 28512424.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Differentiating_vasculitis_from_other_diseases&oldid=1456122"